Compare · ARGX vs CLDI
ARGX vs CLDI
Side-by-side comparison of argenx SE (ARGX) and Calidi Biotherapeutics Inc. (CLDI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CLDI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 16377.0x CLDI ($3.2M).
- ARGX has hit the wire 6 times in the past 4 weeks while CLDI has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 2 for CLDI).
- Company
- argenx SE
- Calidi Biotherapeutics Inc.
- Price
- -
- -
- Market cap
- $52.52B
- $3.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 2
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest CLDI
- SEC Form 8-K filed by Calidi Biotherapeutics Inc.
- Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
- Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events
- SEC Form 424B5 filed by Calidi Biotherapeutics Inc.
- Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
- Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form 4 filed by Chief Financial Officer Jackson Andrew C.
- SEC Form 4 filed by Chief Scientific Officer Fernandez Santidrian Antonio
- SEC Form 4 filed by Director Schoeneck James A
- SEC Form 4 filed by Director Leftwich Scott